AbbVie
1 North Waukegan Road
North Chicago
Illinois
60064
United States
Tel: 1-800-255-5162
Website: http://www.abbvie.com/
Email: customerservice@abbvie.com
About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.
Stock Symbol: ABBV
Stock Exchange: NYSE
We’re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company.
1559 articles with AbbVie
-
Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023
1/25/2023
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today unveiled at the 24th International Master Course on Aging Science (IMCAS) World Congress its immersive experience 'Discover your 360°'.
-
Childhood Cancer Patients and Their Families Find a Home Away From Home
1/24/2023
For the families of children battling childhood cancer and other catastrophic diseases, days are often all but typical.
-
BioMed X and AbbVie Extend Research Collaboration in the USBioMed X establishes its first US-based institute in New Haven with a new immunology research project in collaboration with AbbVie.
1/16/2023
BioMed X, an independent German biomedical research institute, announced today the extension of its ongoing research collaboration with AbbVie.
-
In a fireside chat at the 41st J.P. Morgan Healthcare Conference in San Francisco, CEO Rick Gonzalez said AbbVie is well-positioned for continued growth.
-
Tuesday, AbbVie partnered with Anima Biotech to discover and develop mRNA modulators in a collaboration of up to $582 million. The partnership will focus on three oncology and immunology targets.
-
AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets
1/10/2023
AbbVie (NYSE: ABBV), and Anima Biotech (Anima), today announced a collaboration to discover and develop mRNA biology modulators for three targets across Oncology and Immunology.
-
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
1/6/2023
AbbVie and Immunome, Inc. announced a worldwide collaboration and option agreement directed to the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome's Discovery Engine.
-
AbbVie to Host Fourth-Quarter 2022 Earnings Conference Call
1/5/2023
AbbVie (NYSE: ABBV) will announce its fourth-quarter 2022 financial results on Thursday, February 9, 2023, before the market opens.
-
Frontier Medicines Announces Advancement of Second and Third Programs Under Global Partnership with AbbVie
1/5/2023
Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthroughs against otherwise undruggable disease-causing targets, announced the second and third programs under the company's global partnership with AbbVie have advanced into lead generation.
-
In the past few weeks, the biopharma industry has been filled with layoffs and company launches. To learn about job opportunities at some of the industry's top companies, see inside.
-
AbbVie to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
AbbVie (NYSE: ABBV) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023.
-
U.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder
12/16/2022
AbbVie announced that the U.S. Food and Drug Administration has approved VRAYLAR® as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults.
-
AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age
12/16/2022
AbbVie (NYSE: ABBV) today announced that it has submitted a supplemental New Drug Application (sNDA) for linaclotide (LINZESS®) to the U.S. Food and Drug Administration (FDA) for the treatment of children and adolescents 6 to 17 years of age with functional constipation (FC).
-
AbCellera and AbbVie Partner to Advance New Antibody Therapies
12/15/2022
AbCellera (Nasdaq: ABCL) announced today that it has entered into a multi-year, multi-target strategic collaboration with AbbVie Inc. (NYSE: ABBV).
-
AbbVie and AbCellera inked an antibody discovery deal to develop candidates for up to five targets in several indications.
-
Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements
12/14/2022
Exicure, Inc. an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, announced the termination of its collaboration agreements with AbbVie, Inc. and Ipsen BioPharm Limited.
-
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas
12/11/2022
AbbVie announced data from multiple clinical trials evaluating epcoritamab, an investigational subcutaneous bispecific antibody, alone or in combination for the treatment of patients with relapsed/refractory follicular lymphoma, previously untreated FL, R/R diffuse large B-cell lymphoma, as well as Richter's syndrome at the 64th American Society of Hematology Annual Meeting.
-
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Adds to Robust IMBRUVICA® (ibrutinib) Science
12/10/2022
AbbVie announced new and updated data across clinical and real-world studies in chronic lymphocytic leukemia.
-
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients
12/10/2022
AbbVie announced new data from Cohort 3 of its Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis.
-
Discovery Files: A Vision for Blood Cancer Patients
12/8/2022
In this episode of Discovery Files, we hear from veteran chemist Andy Souers, Ph.D., distinguished research fellow, AbbVie oncology discovery research, on how his team made a blood cancer discovery.